Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Progression02:07

Tumor Progression

7.6K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

4.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.9K
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

3.1K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.1K
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

862
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
862
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Myocarditis IV: Nursing Management01:22

Myocarditis IV: Nursing Management

299
Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...
299

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Immune Effector Cell-Associated Hematotoxicity With Secondary Myelofibrosis Following Idecabtagene-Vicleucel for Multiple Myeloma, Comprehensively Treated With Autologous Hematopoietic Stem Cell Boosting.

EJHaem·2026
Same author

Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trial.

Lancet (London, England)·2026
Same author

TFH phenotype and response to tucidinostat in relapsed/refractory PTCL: analysis of patients from a phase IIb trial.

International journal of hematology·2026
Same author

Long-term outcomes of low-dose dasatinib in older patients with chronic myeloid leukemia in chronic phase: an extended follow-up of the DAVLEC phase 2 trial.

Blood cancer journal·2026
Same author

Fractures beyond spasms: Progressive encephalomyelitis with rigidity and myoclonus associated with GABA-linked bone fragility.

eNeurologicalSci·2026
Same author

Non-infectious fever defines a subgroup of patients with poorer survival outcomes in high-risk myelodysplastic syndrome.

British journal of haematology·2026
Same journal

[Rinsho ketsueki] The Japanese journal of clinical hematology·2026
Same journal

[Rinsho ketsueki] The Japanese journal of clinical hematology·2026
Same journal

[Rinsho ketsueki] The Japanese journal of clinical hematology·2026
Same journal

[Recent advances in pathogenesis, diagnosis, and therapeutic strategies for POEMS syndrome].

[Rinsho ketsueki] The Japanese journal of clinical hematology·2026
Same journal

[Recent advances in management of systemic AL amyloidosis].

[Rinsho ketsueki] The Japanese journal of clinical hematology·2026
Same journal

[Treatment strategies for relapsed or refractory multiple myeloma: proposals for optimal treatment sequencing].

[Rinsho ketsueki] The Japanese journal of clinical hematology·2026
See all related articles

Related Experiment Video

Updated: Mar 1, 2026

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

7.3K

Multiple myeloma: pathophysiology and progress in management.

Junya Kuroda1, Yoshiaki Chinen1

  • 1Division of Hematology and Oncology, Department of Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine.

[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology
|June 9, 2017
PubMed
Summary
This summary is machine-generated.

Recent advances reveal significant diversity in multiple myeloma (MM) pathophysiology and immune factors. Translating molecular and immunologic insights into clinical practice is key for effective MM management and treatment strategies.

Keywords:
Immune dysregulationInter-patient diversityMolecular heterogeneityMultiple myeloma

More Related Videos

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.6K
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

9.1K

Related Experiment Videos

Last Updated: Mar 1, 2026

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

7.3K
Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.6K
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

9.1K

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • Multiple myeloma (MM) exhibits substantial inter-patient diversity and intra-clonal heterogeneity in cytogenetic/molecular abnormalities.
  • Significant variations in immunological factors influencing tumor surveillance exist among MM patients.
  • Novel therapeutic agents, including targeted therapies and immunomodulatory drugs, are transforming MM treatment.

Purpose of the Study:

  • To review recent advancements in understanding the pathophysiology of multiple myeloma (MM).
  • To summarize molecular, cytogenetic, and epigenetic abnormalities in MM.
  • To discuss immunologic dysregulation and innovations in diagnostic and treatment approaches for MM.

Main Methods:

  • Comprehensive literature review of recent research on multiple myeloma.
  • Analysis of molecular, cytogenetic, epigenetic, and immunologic findings in MM.
  • Synthesis of current knowledge on diagnostic and therapeutic strategies for MM.

Main Results:

  • MM is characterized by high heterogeneity at both patient and intra-clonal levels.
  • Immune system dysregulation plays a critical role in MM progression.
  • Advances in understanding MM pathophysiology are driving the development of novel treatments.

Conclusions:

  • Optimal clinical application of molecular and immunologic findings is essential for managing MM.
  • Risk stratification, outcome prediction, and disease monitoring are crucial for MM patient care.
  • Ongoing innovations in diagnostics and treatment concepts continue to improve MM management.